BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36198279)

  • 21. Serum and urine analysis with gold nanoparticle-assisted laser desorption/ionization mass spectrometry for renal cell carcinoma metabolic biomarkers discovery.
    Arendowski A; Ossoliński K; Ossolińska A; Ossoliński T; Nizioł J; Ruman T
    Adv Med Sci; 2021 Sep; 66(2):326-335. PubMed ID: 34273747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
    Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
    Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasonic-assisted extraction and digestion of proteins from solid biopsies followed by peptide sequential extraction hyphenated to MALDI-based profiling holds the promise of distinguishing renal oncocytoma from chromophobe renal cell carcinoma.
    Jorge S; Pereira K; López-Fernández H; LaFramboise W; Dhir R; Fernández-Lodeiro J; Lodeiro C; Santos HM; Capelo-Martínez JL
    Talanta; 2020 Jan; 206():120180. PubMed ID: 31514886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Oncocytoma versus chromophobe renal cell carcinoma: Is there something in between?].
    Lüders C; Kristiansen G
    Pathologe; 2016 Mar; 37(2):153-8. PubMed ID: 26925847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histology-guided proteomic analysis to investigate the molecular profiles of clear cell Renal Cell Carcinoma grades.
    Stella M; Chinello C; Cazzaniga A; Smith A; Galli M; Piga I; Grasso A; Grasso M; Del Puppo M; Varallo M; Bovo G; Magni F
    J Proteomics; 2019 Jan; 191():38-47. PubMed ID: 29698802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
    Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
    J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma.
    Tan MH; Wong CF; Tan HL; Yang XJ; Ditlev J; Matsuda D; Khoo SK; Sugimura J; Fujioka T; Furge KA; Kort E; Giraud S; Ferlicot S; Vielh P; Amsellem-Ouazana D; Debré B; Flam T; Thiounn N; Zerbib M; Benoît G; Droupy S; Molinié V; Vieillefond A; Tan PH; Richard S; Teh BT
    BMC Cancer; 2010 May; 10():196. PubMed ID: 20462447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
    Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
    Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis of uncommon renal epithelial neoplasms: performances of fluorescence in situ hybridization.
    Beaumont M; Dugay F; Kammerer-Jacquet SF; Jaillard S; Cabillic F; Mathieu R; Verhoest G; Bensalah K; Rioux-Leclercq N; Belaud-Rotureau MA;
    Hum Pathol; 2019 Oct; 92():81-90. PubMed ID: 31437522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry.
    Prade VM; Kunzke T; Feuchtinger A; Rohm M; Luber B; Lordick F; Buck A; Walch A
    Mol Metab; 2020 Jun; 36():100953. PubMed ID: 32278304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and clinical value of SALL4 in renal cell carcinomas.
    Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
    Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide Profile Differences of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features, Encapsulated Follicular Variant, and Classical Papillary Thyroid Carcinoma: An Application of Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging.
    Ucal Y; Tokat F; Duren M; Ince U; Ozpinar A
    Thyroid; 2019 Aug; 29(8):1125-1137. PubMed ID: 31064269
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
    Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
    Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic utility of amylase α-1A, MOC 31, and
    Abouhashem NS; Abdelbary EH; H Abdalla MM; El-Shazly M
    Indian J Pathol Microbiol; 2020; 63(3):405-411. PubMed ID: 32769329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HNF1β and S100A1 are useful biomarkers for distinguishing renal oncocytoma and chromophobe renal cell carcinoma in FNA and core needle biopsies.
    Conner JR; Hirsch MS; Jo VY
    Cancer Cytopathol; 2015 May; 123(5):298-305. PubMed ID: 25739652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1.
    Hong SH; Hwang HJ; Son DH; Kim ES; Park SY; Yoon YE
    FEBS Open Bio; 2023 Apr; 13(4):724-735. PubMed ID: 36808829
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor grade estımatıon of clear cell and papıllary renal cell carcınomas usıng contrast-enhanced MDCT and FSE T2 weıghted MR ımagıng: radıology-pathology correlatıon.
    Halefoglu AM; Ozagari AA
    Radiol Med; 2021 Sep; 126(9):1139-1148. PubMed ID: 34100169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential diagnosis of chromophobe renal cell carcinoma and papillary renal cell carcinoma with dual-energy spectral computed tomography.
    Wang D; Huang X; Bai L; Zhang X; Wei J; Zhou J
    Acta Radiol; 2020 Nov; 61(11):1562-1569. PubMed ID: 32088966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.